FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128156980> ?p ?o ?g. }

• W2128156980 endingPage "2972" @default.
• W2128156980 startingPage "2966" @default.
• W2128156980 abstract "ABSTRACT Nosocomial pneumonia and acute peritonitis may be caused by a wide array of pathogens, and combination therapy is often recommended. We have previously shown that imipenem-cilastatin monotherapy was as efficacious as the combination of imipenem-cilastatin plus netilmicin in these two settings. The efficacy of imipenem-cilastatin is now compared to that of piperacillin-tazobactam as monotherapy in patients with nosocomial pneumonia or acute peritonitis. Three hundred seventy one patients with nosocomial pneumonia or peritonitis were randomly assigned to receive either imipenem-cilastatin (0.5 g four times a day) or piperacillin-tazobactam (4.5 g three times a day). Three hundred thirteen were assessable (154 with nosocomial pneumonia and 159 with peritonitis). For nosocomial pneumonia, clinical-failure rates in the piperacillin-tazobactam group (13 of 75 [17%]) and in the imipenem-cilastatin group (23 of 79 [29%]) were similar ( P = 0.09), as were the numbers of deaths due to infection (6 in the imipenem-cilastatin group [8%], 7 in the piperacillin-tazobactam group [9%]) ( P = 0.78). For acute peritonitis, clinical success rates were comparable (piperacillin-tazobactam, 72 of 76 [95%]; imipenem-cilastatin, 77 of 83 [93%]). For infections due to Pseudomonas aeruginosa , 45 patients had nosocomial pneumonia (21 in the piperacillin-tazobactam group and 24 in the imipenem-cilastatin group) and 10 had peritonitis (5 in each group). In the patients with nosocomial pneumonia, clinical failure was less frequent in the piperacillin-tazobactam group (2 of 21 [10%]) than in the piperacillin-cilastatin group (12 of 24 [50%]) ( P = 0.004). Bacterial resistance to allocated regimen was the main cause of clinical failure (1 in the piperacillin-tazobactam group and 12 in the imipenem-cilastatin group). For the patients with peritonitis, no difference in clinical outcome was observed (five of five cured in each group). The overall frequencies of adverse events related to treatment in the two groups were similar (24 in the piperacillin-tazobactam group, 22 in the imipenem-cilastatin group). Diarrhea was significantly more frequent in the piperacillin-tazobactam group (10 of 24) than in the imipenem-cilastatin group (2 of 22). This study suggests that piperacillin-tazobactam monotherapy is at least as effective and safe as imipenem-cilastatin monotherapy in the treatment of nosocomial pneumonia or peritonitis. In P. aeruginosa pneumonia, piperacillin-tazobactam achieved a better clinical efficacy than imipenem-cilastatin, due to reduced development of microbiological resistance. Tolerance was comparable, with the exception of diarrhea, which was more frequent with piperacillin-tazobactam." @default.
• W2128156980 created "2016-06-24" @default.
• W2128156980 creator A5012274468 @default.
• W2128156980 creator A5021809692 @default.
• W2128156980 creator A5023167642 @default.
• W2128156980 creator A5032876625 @default.
• W2128156980 creator A5037469107 @default.
• W2128156980 creator A5040335172 @default.
• W2128156980 creator A5061843949 @default.
• W2128156980 creator A5062196748 @default.
• W2128156980 creator A5062570606 @default.
• W2128156980 creator A5063814087 @default.
• W2128156980 creator A5066242098 @default.
• W2128156980 creator A5069689198 @default.
• W2128156980 creator A5072001348 @default.
• W2128156980 creator A5078263808 @default.
• W2128156980 creator A5082545866 @default.
• W2128156980 creator A5089646295 @default.
• W2128156980 date "1998-11-01" @default.
• W2128156980 modified "2023-10-13" @default.
• W2128156980 title "Prospective Randomized Comparison of Imipenem-Cilastatin and Piperacillin-Tazobactam in Nosocomial Pneumonia or Peritonitis" @default.
• W2128156980 cites W1571178250 @default.
• W2128156980 cites W162125722 @default.
• W2128156980 cites W1969282813 @default.
• W2128156980 cites W1972711635 @default.
• W2128156980 cites W1974787784 @default.
• W2128156980 cites W197715925 @default.
• W2128156980 cites W1978581575 @default.
• W2128156980 cites W1981612169 @default.
• W2128156980 cites W1984864482 @default.
• W2128156980 cites W1984883296 @default.
• W2128156980 cites W1987986939 @default.
• W2128156980 cites W1993542905 @default.
• W2128156980 cites W2000845316 @default.
• W2128156980 cites W2004449157 @default.
• W2128156980 cites W2011483204 @default.
• W2128156980 cites W2013500891 @default.
• W2128156980 cites W2015842254 @default.
• W2128156980 cites W2021281598 @default.
• W2128156980 cites W202397887 @default.
• W2128156980 cites W2025801951 @default.
• W2128156980 cites W2026649947 @default.
• W2128156980 cites W2026855333 @default.
• W2128156980 cites W2036934691 @default.
• W2128156980 cites W2042674047 @default.
• W2128156980 cites W2045905147 @default.
• W2128156980 cites W2046762565 @default.
• W2128156980 cites W2054568631 @default.
• W2128156980 cites W2070661219 @default.
• W2128156980 cites W2071812276 @default.
• W2128156980 cites W2073060575 @default.
• W2128156980 cites W2086773685 @default.
• W2128156980 cites W2087692099 @default.
• W2128156980 cites W2091955762 @default.
• W2128156980 cites W2100603233 @default.
• W2128156980 cites W2104923518 @default.
• W2128156980 cites W2108403967 @default.
• W2128156980 cites W2150503785 @default.
• W2128156980 cites W2151629261 @default.
• W2128156980 cites W2168937912 @default.
• W2128156980 cites W2271455920 @default.
• W2128156980 cites W2331267603 @default.
• W2128156980 cites W2482654371 @default.
• W2128156980 cites W4205279 @default.
• W2128156980 cites W84061989 @default.
• W2128156980 doi "https://doi.org/10.1128/aac.42.11.2966" @default.
• W2128156980 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/89196" @default.
• W2128156980 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9797234" @default.
• W2128156980 hasPublicationYear "1998" @default.
• W2128156980 type Work @default.
• W2128156980 sameAs 2128156980 @default.
• W2128156980 citedByCount "153" @default.
• W2128156980 countsByYear W21281569802012 @default.
• W2128156980 countsByYear W21281569802013 @default.
• W2128156980 countsByYear W21281569802014 @default.
• W2128156980 countsByYear W21281569802015 @default.
• W2128156980 countsByYear W21281569802016 @default.
• W2128156980 countsByYear W21281569802017 @default.
• W2128156980 countsByYear W21281569802018 @default.
• W2128156980 countsByYear W21281569802019 @default.
• W2128156980 countsByYear W21281569802020 @default.
• W2128156980 countsByYear W21281569802021 @default.
• W2128156980 countsByYear W21281569802022 @default.
• W2128156980 countsByYear W21281569802023 @default.
• W2128156980 crossrefType "journal-article" @default.
• W2128156980 hasAuthorship W2128156980A5012274468 @default.
• W2128156980 hasAuthorship W2128156980A5021809692 @default.
• W2128156980 hasAuthorship W2128156980A5023167642 @default.
• W2128156980 hasAuthorship W2128156980A5032876625 @default.
• W2128156980 hasAuthorship W2128156980A5037469107 @default.
• W2128156980 hasAuthorship W2128156980A5040335172 @default.
• W2128156980 hasAuthorship W2128156980A5061843949 @default.
• W2128156980 hasAuthorship W2128156980A5062196748 @default.
• W2128156980 hasAuthorship W2128156980A5062570606 @default.
• W2128156980 hasAuthorship W2128156980A5063814087 @default.
• W2128156980 hasAuthorship W2128156980A5066242098 @default.
• W2128156980 hasAuthorship W2128156980A5069689198 @default.
• W2128156980 hasAuthorship W2128156980A5072001348 @default.

• next